Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544908 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00544908 is a Phase 2 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT00544908, a Phase 2 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG dasatinib
- OTHER immunohistochemistry staining method
- PROCEDURE quality-of-life assessment
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00544908
The ClinicalTrials.gov registry entry for NCT00544908 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00544908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00544908 about?
NCT00544908 is a clinical study titled "Dasatinib in Treating Patients With Stage IV Pancreatic Cancer". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.
What is the current status of trial NCT00544908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-09.
What interventions are being tested in trial NCT00544908?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dasatinib (DRUG), immunohistochemistry staining method (OTHER), quality-of-life assessment (PROCEDURE), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00544908?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.